Journal of Microbiology

Journal Article

Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells: Jeong-Soo Park , Manbok Kim; J. Microbiol. 2017;55(1):75-79. Published online December 30, 2016; DOI: https://doi.org/10.1007/s12275-017-6542-0

49 View
0 Download
8 Crossref

Naturally occurring reoviruses are live replication-proficient viruses specifically infecting human cancer cells while sparing the normal counterparts. Stem cells can be highly susceptible to viral infection due to their innate high proliferation potential and other active signaling pathways of cells that might be involved in viral tropism. In the previous study, we showed that reoviruses could adversely affect murine embryonic stem cells’ integrity in vitro and in vivo. Oncolytic viruses, delivered systemically face many hurdles that also impede their localization and infection of, metastatic tumors, due to a variety of immune and physical barriers. To overcome such hurdles to systemic delivery, several studies supported the idea that certain types of cells, including mesenchymal stem cells, might play a role as cell carriers for oncolytic viruses. Thus, it would be interesting to examine whether human adult stem cells such as human adipose-derived mesenchymal stem cells could be saved by the reoviral challenge. In this study, we report that biological activities such as proliferation and multipotency of human adipose-derived stem cells are not affected by wild-type reovirus challenge as evidenced by survival, osteogenic and adipogenic differentiation potential assays following treatment with reoviruses. Therefore, unlike murine embryonic stem cells, our study strongly suggests that human adipose-derived adult stem cells could be spared in vivo during wild-type reoviral anti-cancer therapeutics in a clinical setting. Furthermore, the results support the possible clinical use of human adipose-derived stem cells as an effective cell carrier of oncolytic reovirus to maximize their tumor tropism and anti-tumor activity.

Citations

Citations to this article as recorded by

Modulation of Reoviral Cytolysis (II): Cellular Stemness
Tarryn Bourhill, Leili Rohani, Mehul Kumar, Pinaki Bose, Derrick Rancourt, Randal N. Johnston
Viruses.2023; 15(7): 1473. CrossRef
Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia
Xianyao Wang, Yichen Yang, Nianxue Wang, Xijun Wu, Jianwei Xu, Yanhua Zhou, Xing Zhao, Zhixu He
International Immunopharmacology.2021; 94: 107437. CrossRef
Mesenchymal stem cells support delivery and boost the efficacy of oncolytic reoviruses in TC‐1 tumor cells
Razieh S. Banijamali, Hoorieh Soleimanjahi, Sara Soudi, Hesam Karimi
Journal of Cellular Biochemistry.2021; 122(10): 1360. CrossRef
Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses
Agata Hadryś, Aleksander Sochanik, Grant McFadden, Joanna Jazowiecka-Rakus
European Journal of Pharmacology.2020; 874: 172991. CrossRef
Recent advances in targeting cancer stem cells using oncolytic viruses
You-Ni Zhang, Shi-Bing Wang, Shu-Shu Song, Pei-Yang Hu, Yu-Cheng Zhou, Yi-Ping Mou, Xiao-Zhou Mou
Biotechnology Letters.2020; 42(6): 865. CrossRef
The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice
Ruimin Cai, Guangyuan Meng, Yi Li, Wenyang Wang, Youxiang Diao, Shuping Zhao, Qiang Feng, Yi Tang
Experimental Biology and Medicine.2019; 244(12): 983. CrossRef
Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
Tarryn Bourhill, Yoshinori Mori, Derrick Rancourt, Maya Shmulevitz, Randal Johnston
Viruses.2018; 10(8): 421. CrossRef
Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas
Sangmin Kang, Jinjong Myoung
Journal of Microbiology.2017; 55(5): 319. CrossRef

Review

Replicating poxviruses for human cancer therapy: Manbok Kim; J. Microbiol. 2015;53(4):209-218. Published online April 8, 2015; DOI: https://doi.org/10.1007/s12275-015-5041-4

57 View
0 Download
24 Crossref

Abstract

Naturally occurring oncolytic viruses are live, replicationproficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the eradication of smallpox in the 1970s with the aid of vaccinia viruses, the vaccinia viruses and other genera of poxviruses have shown various degrees of safety and efficacy in pre-clinical or clinical application for human anti-cancer therapeutics. Furthermore, we have recently discovered that cellular tumor suppressor genes are important in determining poxviral oncolytic tropism. Since carcinogenesis is a multi-step process involving accumulation of both oncogene and tumor suppressor gene abnormalities, it is interesting that poxvirus can exploit abnormal cellular tumor suppressor signaling for its oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity/maintenance. Thus, tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects, which would in turn result in oncolytic virus susceptibility. This review outlines the characteristics of oncolytic poxvirus strains, including vaccinia, myxoma, and squirrelpox virus, recent progress in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and poxviral oncolytic tropism, and the associated preclinical/clinical implications. I would also like to propose future directions in the utility of poxviruses for oncolytic virotherapy.

Citations

Citations to this article as recorded by

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy
Shashi Gujar, Jonathan G. Pol, Vishnupriyan Kumar, Manuela Lizarralde-Guerrero, Prathyusha Konda, Guido Kroemer, John C. Bell
Nature Protocols.2024; 19(9): 2540. CrossRef
A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells
Yanrong Zhou, Qianpeng Wang, Qi Ying, Xiaomei Zhang, Ting Ye, Kan Chen, Gongchu Li
Marine Drugs.2023; 21(2): 77. CrossRef
Poxvirus-driven human diseases and emerging therapeutics
Kritika Srinivasan Rajsri, Mana Rao
Therapeutic Advances in Infectious Disease.2022;[Epub] CrossRef
The O H system: A panorama view of the PPV-host interaction
Yongzhong Yu, Zhengxing Lian, Yudong Cui
Infection, Genetics and Evolution.2022; 98: 105220. CrossRef
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, Nozomi Kuwano, Masato Yamane, Kenta Ishii, Yoshiyuki Fujiwara, Takafumi Nakamura
Cells.2021; 10(5): 985. CrossRef
Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo
Xue Wang, Ningning Zhou, Tingting Liu, Xiaoyuan Jia, Ting Ye, Kan Chen, Gongchu Li
Marine Drugs.2021; 19(6): 292. CrossRef
Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity
Su-Nam Jeong, So Young Yoo
Cancers.2020; 12(5): 1070. CrossRef
Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status
Yuhui Zhang, Zhuoming Liu
Current Pharmaceutical Design.2020; 25(40): 4251. CrossRef
Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS–STING signalling
James B. Eaglesham, Youdong Pan, Thomas S. Kupper, Philip J. Kranzusch
Nature.2019; 566(7743): 259. CrossRef
Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus
A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva
Molecular Genetics Microbiology and Virology (Russian version).2019; 37(2): 83. CrossRef
Poxvirus oncolytic virotherapy
Lino E. Torres-Domínguez, Grant McFadden
Expert Opinion on Biological Therapy.2019; 19(6): 561. CrossRef
Targeted Therapy of Human Glioblastoma Combining the Oncolytic Properties of Parvovirus H-1 and Attenuated Strains of the Vaccinia Virus
A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva
Molecular Genetics, Microbiology and Virology.2019; 34(2): 140. CrossRef
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
Edmund K. Moon, Liang-Chuan S. Wang, Kheng Bekdache, Rachel C. Lynn, Albert Lo, Stephen H. Thorne, Steven M. Albelda
OncoImmunology.2018; 7(3): e1395997. CrossRef
Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer
Michael White, Andrew Freistaedter, Gwendolyn J. B. Jones, Emmanuel Zervos, Rachel L. Roper, Aamir Ahmad
PLOS ONE.2018; 13(2): e0193131. CrossRef
Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol
Rutger David Luteijn, Ingo Drexler, Geoffrey L. Smith, Robert Jan Lebbink, Emmanuel J. H. J. Wiertz
Journal of General Virology.2018; 99(6): 790. CrossRef
Oncolytic viruses: emerging options for the treatment of breast cancer
Yogesh R. Suryawanshi, Tiantian Zhang, Karim Essani
Medical Oncology.2017;[Epub] CrossRef
Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas
Sangmin Kang, Jinjong Myoung
Journal of Microbiology.2017; 55(5): 319. CrossRef
Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro
Elena P. Goncharova, Julia S. Ruzhenkova, Ivan S. Petrov, Sergey N. Shchelkunov, Marina A. Zenkova
Journal of Translational Medicine.2016;[Epub] CrossRef
Oncolytic virotherapy for urological cancers
Zahid Delwar, Kaixin Zhang, Paul S. Rennie, William Jia
Nature Reviews Urology.2016; 13(6): 334. CrossRef
Features of the Antitumor Effect of Vaccinia Virus Lister Strain
Evgeniy Zonov, Galina Kochneva, Anastasiya Yunusova, Antonina Grazhdantseva, Vladimir Richter, Elena Ryabchikova
Viruses.2016; 8(1): 20. CrossRef
Single-particle characterization of oncolytic vaccinia virus by flow virometry
Vera A. Tang, Tyler M. Renner, Oliver Varette, Fabrice Le Boeuf, Jiahu Wang, Jean-Simon Diallo, John C. Bell, Marc-André Langlois
Vaccine.2016; 34(42): 5082. CrossRef
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors
Sally Al Ali, Sara Baldanta, Mercedes Fernández-Escobar, Susana Guerra
Viruses.2016; 8(5): 134. CrossRef
Naturally occurring reoviruses for human cancer therapy
Manbok Kim
BMB Reports.2015; 48(8): 454. CrossRef
Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells
Manbok Kim
Journal of Bacteriology and Virology.2015; 45(2): 126. CrossRef

First
Prev
Page of 1
Next
Last

Search